Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: A California Cancer Consortium Trial

R. J. Morgan, T. W. Synold, D. Gandara, F. Muggia, S. Scudder, E. Reed, K. Margolin, J. Raschko, L. Leong, S. Shibata, M. Tetef, S. Vasilev, K. McGonigle, J. Longmate, Y. Yen, W. Chow, G. Somlo, M. Carroll, J. H. Doroshow

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. OC patients relapsing following platinum-based chemotherapy received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The pharmacokinetics of CSA and CBDCA were determined in a subset of patients. Thirty patients received 84 courses of therapy. Three partial responses were observed. Nine patients were stable for >4 months. Toxicity was similar to that observed in our previously reported phase I study and consisted of myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA level (high-performance liquid chromatographic assay [HPLC]) was 1109 ± 291 μg/mL (mean ± SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance. Steady-state levels of >1 μg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 2007

Keywords

  • Chemomodulation
  • Chemotherapy
  • Phase II

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: A California Cancer Consortium Trial'. Together they form a unique fingerprint.

  • Cite this

    Morgan, R. J., Synold, T. W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K., Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Y., Chow, W., Somlo, G., Carroll, M., & Doroshow, J. H. (2007). Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: A California Cancer Consortium Trial. International Journal of Gynecological Cancer, 17(2), 373-378. https://doi.org/10.1111/j.1525-1438.2007.00787.x